Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial apoptosis-inducing factor 1 (AIFM1) is a flavoprotein that functions both as an NADH oxidoreductase involved in oxidative phosphorylation and as a key mediator of caspase-independent apoptosis. In healthy cells, AIF is anchored to the inner mitochondrial membrane, where it contributes to mitochondrial respiration and cristae structure[2]. Upon apoptotic stimuli, AIF is cleaved, released from the mitochondria, and translocated to the nucleus, where it induces large-scale DNA fragmentation and chromatin condensation, independent of caspases[1][2]. AIF is also implicated in mitochondrial bioenergetics and may associate with respiratory chain complexes, such as cytochrome c oxidase, possibly modulating their activity or stability[3]. Dysregulation or mutations in AIF are associated with neurodegenerative diseases, severe mitochondrial dysfunction, and possibly other pathologies involving apoptosis or bioenergetic failure[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial apoptosis-inducing factor 1 (AIF).